Episode 182 - David Solomon - CEO of Thalia Therapeutics

We were delighted to be joined by Dr. David Solomon, Chief Executive Officer of Thalia Therapeutics, onto The BioHub!

David brings more than three decades of leadership experience across the biotechnology, pharmaceutical, and healthcare sectors, having led multiple publicly listed and private biotech companies throughout Europe and the United States. Throughout his career, he has played a key role in advancing innovative therapies, scaling organisations, securing major strategic partnerships, and delivering significant shareholder value.

Prior to joining Thalia Therapeutics, David served as CEO of companies including Zealand Pharma, where he led the business through its IPO and the global approval of its lead GLP-1 therapy, and Silence Therapeutics, helping position the company as a leading player in the RNA therapeutics space. He has also held numerous board positions and remains a highly respected figure across the global biotech ecosystem.

At Thalia Therapeutics, David is leading the company’s strategic focus on next-generation RNA therapeutics and novel delivery technologies, with ambitions to address major unmet needs across cardiovascular disease, oncology, and beyond.